Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.

Accordingly, there may be significant concern that none of the NSAID treatment or prevention trials used “anti‐inflammatory” agents that would be likely to affect the changes described by Rogers, McGeer, et al. 109 , 110 6.6 Concluding thoughts on the disparity between the NSAID trial and observational results The earliest published work on this topic considered the possibility of confounding by indication.

also in 13,097 other papers

Exploratory sub‐group analysis showed that participants on n‐3 PUFA supplementation with a low omega‐3 index (DHA + EPA ≤4.83%, representing the lowest quartile of omega‐3 index distribution) at baseline showed a trend toward less cognitive decline over 36 months in comparison to subjects on placebo with low baseline omega‐3 index. 172 PREVENTE4 ( NCT03613844 ) is testing whether high dose (2 g/day) algal‐derived DHA supplementation over 2 years would benefit non‐demented older individuals with low baseline o

also in 53,322 other papers